Clinical trials: Digestive Tract Diseases
Common Bile Duct Stone
Treatment of Common Bile Duct Stones
ABSTRACT Introduction: Common bile duct (CBD) stone is a common clinical situation, especially in Asia area. Laparotomy and laparoscopic surgical procedure are often used for treatment.
- Trial name
- NCT03442205
- Testing
- LC + LCBDE + ENBD + primary closure of CBD, ERCP technique + LC, LC + LCBDE + primary closure of CBD
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Tongji Hospital
Primary Biliary Cholangitis
Study to Evaluate Safety, Tolerability and Pharmacokinetics of CS0159 in Chinese Healthy Subjects
This is a phase I clinical bridging trial, randomized, double-blind, placebo-controlled, single ascending does/ mulelple ascending does study of CS0159 to evaluate the safety, tolerability, pharmacokynetics, pharmacodynamices…
- Trial name
- NCT05624294
- Testing
- CS0159
- Where
- China
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Cascade Pharmaceuticals, Inc
Carcinoma, Pancreatic Ductal, Colorectal Neoplasms
A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.
The purpose of this study is to learn about the safety and effects of the study medicine alone or when given together with other anti-cancer therapies. This study also aims to find the best dose.
- Conditions
- Carcinoma, Pancreatic Ductal, Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung
- Trial name
- NCT06447662
- Testing
- PF-07934040, Gemcitabine, Nab-paclitaxel
- Where
- 27 sites in United States, Puerto Rico
- Volunteers
- 64 people
- Sponsor
- Pfizer
KRAS G12C Mutant Solid Tumors, Carcinoma, Non-Small-Cell Lung
Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation
This is a phase Ib/II open label study. The escalation part will characterize the safety and tolerability of JDQ443 single agent and JDQ443 in combination with the other study treatments (TNO155 and tislelizumab) in advanced…
- Conditions
- KRAS G12C Mutant Solid Tumors, Carcinoma, Non-Small-Cell Lung, Carcinoma, Colorectal, Cancer of Lung
- Trial name
- KontRASt-01 (NCT04699188)
- Testing
- JDQ443, TNO155, tislelizumab
- Where
- 38 sites in United States, Australia and 14 more
- Volunteers
- 344 people
- Sponsor
- Novartis Pharmaceuticals
Lung Cancers, Liver Cancer
AI-Assisted Non-Contrast CT for Multi-Cancer Screening
Cancer poses a major public health challenge in China. Early detection can improve treatment outcomes and survival rates. In this study, we will conduct a large-scale, prospective, multi-center cohort study to evaluate the…
- Conditions
- Lung Cancers, Liver Cancer, Gastric Cancers, Colorectal, Cancer
- Trial name
- NCT06632886
- Testing
- AI-Assisted Non-Contrast CT for Multi-Cancer Screening
- Where
- China
- Volunteers
- 1,000,000 people, healthy volunteers welcome
- Sponsor
- Guo ShiWei
Cholestasis, Intrahepatic Cholestasis of Pregnancy
Investigation of the Pruritogens of Liver-related Diseases
This study hopes investigate the itch-inducing ability of different potential pruritogen candidates of cholestasis pruritus, especially the intrahepatic cholestasis of pregnancy (ICP).
- Trial name
- NCT06364969
- Where
- China
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Peking University
Breast Cancer, Colon Cancer
Copper Cu 64 Anti-CEA Monoclonal Antibody M5A PET in Diagnosing Patients With CEA Positive Cancer
This pilot clinical trial studies copper Cu 64 anti-carcinoembryonic antigen (CEA) monoclonal antibody M5A positron emission tomography (PET) in diagnosing patients with CEA positive cancer.
- Conditions
- Breast Cancer, Colon Cancer, Extrahepatic Bile Duct Cancer, Gallbladder Cancer
- Trial name
- NCT02293954
- Testing
- radionuclide imaging, positron emission tomography, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- City of Hope Medical Center
Primary Sclerosing Cholangitis, Liver Transplant, Complications
Pharmacologic Approaches to Preventing Primary Sclerosing Cholangitis Recurrence After Liver Transplantation
This study aims to determine the efficacy of 36 months once-daily fenofibrate in preventing clinically-detectable recurrence of primary sclerosing cholangitis after liver transplantation, compared with a historical control cohort…
- Conditions
- Primary Sclerosing Cholangitis, Liver Transplant, Complications, PSC, Biliary Strictures
- Trial name
- NCT06905054
- Testing
- Fenofibrate (drug), Blood draw for the laboratory assessment, MRI using a hepatobiliary phase contrast agent (Gd-EOB-DPTA)
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Mayo Clinic
Relapsing Remitting Multiple Sclerosis (RRMS)
Indole-3-PROpionic Acid Clinical Trials - Multiple Sclerosis
This study, iPROACT-MS, is part of the iPROACT group of clinical trials aiming to investigate the effects of oral supplementation with indole-3-propionic acid (IPA) in humans.
- Trial name
- iPROACT-MS (NCT07318129)
- Testing
- Indole-3-propionic acid (IPA)
- Where
- Denmark
- Volunteers
- 220 people
- Sponsor
- Glostrup University Hospital, Copenhagen
Primary Biliary Cirrhosis
The Health Burden of Primary Biliary Cirrhosis (PBC) in Switzerland
PBC is a rare, autoimmune, cholestatic liver disease with genetic and environmental pathogenetic factors. Data about epidemiology of PBC in Switzerland are completely lacking.
- Trial name
- NCT02846896
- Where
- Switzerland
- Volunteers
- 501 people
- Sponsor
- Fondazione Epatocentro Ticino
Head and Neck Cancer, Breast Cancer
Evaluation of Improved Onboard Patient Imaging
The primary objective of radiation therapy is to deliver a therapeutic dose of radiation precisely to the target while minimizing exposure to healthy surrounding tissues.
- Conditions
- Head and Neck Cancer, Breast Cancer, Upper Gastrointestinal Cancer, Lung Cancer
- Trial name
- NCT06187103
- Testing
- HyperSight Imaging
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Varian, a Siemens Healthineers Company
Metastatic Pancreatic Cancer, Metastatic Biliary Tract Cancer
Immune Checkpoint Inhibition in Combination With Radiation Therapy in Pancreatic Cancer or Biliary Tract Cancer Patients
This is a prospective, randomized, open-label phase 2 study in patients with metastatic PC or BTC refractory or intolerant to at least one line of prior systemic chemotherapy with gemcitabine or platinum-containing regimens to…
- Trial name
- CheckPAC (NCT02866383)
- Testing
- Nivolumab, Ipilimumab, Radiotherapy
- Where
- Denmark
- Volunteers
- 160 people
- Sponsor
- Herlev Hospital
Cough, Gastroesophageal Reflux
Exhaled Breath Condensate pH in Patients With Cough Caused by Gastroesophageal Reflux
Cough is the most common complaint for which patients seek medical attention in the United States, accounting for approximately 1 billion dollars in health care expenses annually.
- Trial name
- NCT00451841
- Testing
- RTube Exhaled Breath Condensate Collection System
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Massachusetts, Worcester
Prediabetes (Insulin Resistance, Impaired Glucose Tolerance), Female
Wild Blueberries for Gut, Brain, and Cardiometabolic Health in Prediabetes
The goal of this clinical trial is to determine the effectiveness of using a freeze-dried wild blueberry powder on cardiometabolic health, cognitive function, and gut microbiota composition in adult women with prediabetes.
- Conditions
- Prediabetes (Insulin Resistance, Impaired Glucose Tolerance), Female, Adult, Endothelial Function (Reactive Hyperemia)
- Trial name
- NCT06735651
- Testing
- Wild Blueberry
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Georgia State University
COVID, Pneumonia
Bacteriotherapy in the Treatment of COVID-19
In light of its high morbidity and mortality, COronaVIrus Disease 19 (COVID-19) pandemic spread is considered an unprecedented global health challenge.
- Conditions
- COVID, Pneumonia, Diarrhea
- Trial name
- BACT-ovid (NCT04368351)
- Testing
- SivoMixx (200 billion), Azithromycin, hydroxychloroquine
- Where
- Italy
- Volunteers
- 70 people
- Sponsor
- University of Roma La Sapienza
Intestinal Diseases, Helminthiasis
Efficacy of Albendazole to Treat Intestinal Helminths and Its Effect on Gut Microflora
Albendazole is a main anti-helminth, however there is a lack of data regarding its efficacy in the school children population. The aim of this study is to evaluate the efficacy of the albendazole one versus two and three doses…
- Trial name
- NCT01192802
- Testing
- albendazole
- Where
- Gabon
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Albert Schweitzer Hospital
Cystic Fibrosis
ENHANCE- Establishing Natural History in an Advanced New CF Care Era
Measured outcomes for people with CF have improved dramatically over the last 20 years, even prior to the widespread introduction of cystic fibrosis transmembrane conductance regulator (CTFR) modulator treatments.
- Trial name
- NCT05986045
- Testing
- Quality of Life
- Volunteers
- 550 people, healthy volunteers welcome
- Sponsor
- Royal College of Surgeons, Ireland
Primary Biliary Cirrhosis
Mesenchymal Stem Cell Transplantation for Refractory Primary Biliary Cholangitis
Ursodeoxycholic acid is the mainstay treatment medicine for primary biliary cholangitis(PBC). About 1/3 of the patients do not respond to UDCA, which is defined as refractory PBC.
- Trial name
- NCT03668145
- Where
- China
- Volunteers
- 140 people
- Sponsor
- Xijing Hospital of Digestive Diseases
Cystic Fibrosis, Pseudomonas Aeruginosa
Nasal Inhalation of Tobramycin in Patients With Cystic Fibrosis and Pseudomonas Aeruginosa Colonization
The purpose of this study is to determine whether the nasal inhalation of Gernebcin® is effective to decrease the Pseudomonas aeruginosa bacterial count in the nasal lavage fluid.
- Trial name
- NCT00774072
- Testing
- Tobramycin (Gernebcin®)
- Where
- 2 sites in Germany
- Volunteers
- 9 people
- Sponsor
- University of Jena
Melanoma, Breast Carcinoma
A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors
This is a Phase 1, multiple dose, ascending dose escalation study to define a MTD/RD and regimen of XmAb20717, to describe safety and tolerability, to assess PK and immunogenicity, and to preliminarily assess anti-tumor activity…
- Conditions
- Melanoma, Breast Carcinoma, Hepatocellular Carcinoma, Urothelial Carcinoma
- Trial name
- DUET-2 (NCT03517488)
- Testing
- XmAb20717
- Where
- 17 sites in United States
- Volunteers
- 150 people
- Sponsor
- Xencor, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.